SCHEMBL3608942

SCHEMBL3608942

O=S1(=O)Nc2cccc(F)c2N1c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.36
KDM4E B2RXH2 1/20 0.33
RECQL P46063 1/20 0.33
PDE7A Q13946 1/20 0.32
SLC6A2 P23975 2/20 0.32
SLC6A4 P31645 2/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA4 P22748 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
HTR3A P46098 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3602880 0.84 SLC6A2 (0.39) SLC6A2SLC6A4
SCHEMBL3610877 0.79 OPRL1 (0.40) KDM4ERECQLPDE7ASLC6A2SLC6A4
SCHEMBL3595632 0.76 SLC6A2 (0.36) SLC6A2SLC6A4CA12CA1CA2
SCHEMBL3607322 0.74 CA12 (0.37) PTPN1SLC6A2SLC6A4CA12CA1
SCHEMBL3596885 0.74 PTPN1 (0.41) PTPN1KDM4ERECQLSLC6A2SLC6A4
SCHEMBL3604966 0.71 MEN1 (0.39) KDM4ERECQLSLC6A2SLC6A4
SCHEMBL3608728 0.71 OPRL1 (0.36) KDM4ERECQLPDE7ACA12CA1
SCHEMBL11525997 0.70 KDM4E (0.55) PTPN1KDM4ERECQLPDE7ACA12
SCHEMBL4063463 0.70 SLC6A2 (0.39) PTPN1SLC6A2SLC6A4CA12CA1
SCHEMBL3608555 0.69 SLC6A2 (0.38) KDM4ERECQLSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2010-02-04 US disclosed
US-7601722-B2 Aryl sulfamide derivatives and methods of their use WYETH (US) 2009-10-13 US disclosed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP disclosed
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-10 US disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 PTPN1 1633/4885KDM4E 3158/4885RECQL 2631/4885
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 PTPN1 2586/4885KDM4E 3015/4885RECQL 2585/4885
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 PTPN1 1633/4885KDM4E 3158/4885RECQL 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.